

**Embassy of India  
Tashkent**

**Press Release**

Embassy of India, Tashkent has been closely following the developments related to the unfortunate death of 18 children in Uzbekistan due to alleged contamination of the cough syrup Dok1 Max manufactured by an Indian company, Marion Biotech, NOIDA, Uttar Pradesh. The Embassy expresses its sincere condolences to the family members of the victims of this tragedy. The Embassy has maintained contacts with the Agency on Development of Pharmaceutical Industry and has requested the Agency to share its investigation reports with the Indian side so that necessary action may also be taken in India.

Under directions of the Ministry of Health & Family Welfare, Government of India, the Central Drugs Standard Control Organisation (CDSCO) of India has also been maintaining regular contact with the national drug regulator of Uzbekistan since 27th December, 2022.

Immediately on receipt of the information, joint inspection of the NOIDA facility of the manufacturer, Marion Biotech, was carried out by Uttar Pradesh Drug Control and CDSCO team and further action as appropriate would be initiated based on the inspection report.

Marion Biotech is a licensed manufacturer and holds license for manufacturing of Dok1 Max syrup and Tablet for export purpose granted by Drugs Controller, Uttar Pradesh.

The samples of the cough syrup have been taken from the manufacturing premises and sent to the Regional Drugs Testing Laboratory (RDTL), Chandigarh, India for testing.

India values its partnership with Uzbekistan and cooperation in the field of healthcare and pharmaceutical drugs. We will continue to maintain close touch with the Uzbek authorities in this matter.

\*\*\*\*\*

Tashkent  
December 29, 2022